Risk of mature B‐cell neoplasms and precursor conditions after joint replacement: A report from the Haematological Malignancy Research Network

Authors:

Abstract
Associations between previous joint replacement and B‐cell lymphoid malignancies have been reported, but despite numerous reports, associations with the disease subtypes have received little attention. Using a UK‐based register of haematological malignancies and a matched general population‐based cohort, joint replacements from linked hospital inpatient records were examined. Cases diagnosed 2009–2015 who were aged 50 years or more were included; 8,013 mature B‐cell neoplasms comprising myeloma (n = 1,763), diffuse large B‐cell lymphoma (DLBCL, n = 1,676), chronic lymphocytic leukaemia (CLL, n = 1,594), marginal zone lymphoma (MZL, n = 957), follicular lymphoma (FL, n = 725) and classical Hodgkin lymphoma (CHL, n = 255), together with monoclonal gammopathy of uncertain significance (MGUS, n = 2,138) and monoclonal B‐cell lymphocytosis (MBL, n = 632). Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated relative to 10 age‐ and sex‐matched controls using conditional logistic regression. Having had a joint replacement before diagnosis was associated with myeloma (OR = 1.3, 95% CI 1.1–1.5, p = 0.008) and MGUS (OR = 1.3, 95% CI 1.1–1.5, p < 0.001). Excluding replacements in the year before diagnosis, the MGUS risk remained, elevated where two or more joints were replaced (OR = 1.5, 95% CI 1.2–2.0, p = 0.001), with hip (OR = 1.2, 95% CI 1.0–1.5, p = 0.06) or knee replacements (OR = 1.5, 95% CI 1.2–1.8, p < 0.001). Associations with CHL and two or more replacements (OR = 2.7, 95% CI 1.3–5.6, p = 0.005) or hip replacements (OR = 1.9, 95% CI 1.0–3.4, p = 0.04); and between DLBCL and knee replacements (OR = 1.3, 95% CI 1.0–1.6, p = 0.04) were also observed. Our study reports for the first time a relationship between joint replacements and MGUS; while absolute risks of disease are low and not of major public health concern, these findings warrant further investigation.
Funding Information
  • Bloodwise (15037)
  • Cancer Research UK (18362)

This publication has 43 references indexed in Scilit: